Cite
HARVARD Citation
Nishimura, S. et al. (2007). Phase II study of irinotecan plus doxorubicin for early recurrent or platinum-refractory ovarian cancer: interim analysis. International journal of gynecological cancer. 17 (1), pp. 159-163. [Online].